Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Capital Expenditures (2016 - 2025)

Sunshine Biopharma's Capital Expenditures history spans 10 years, with the latest figure at -$1039.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 101.01% year-over-year to -$1039.0; the TTM value through Dec 2025 reached $174491.0, down 89.47%, while the annual FY2025 figure was $174491.0, 89.47% down from the prior year.
  • Capital Expenditures reached -$1039.0 in Q4 2025 per SBFM's latest filing, down from $8040.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $974513.0 in Q2 2024 to a low of -$382363.0 in Q4 2023.
  • Average Capital Expenditures over 4 years is $150254.5, with a median of $62937.0 recorded in 2024.
  • Peak YoY movement for Capital Expenditures: crashed 297.11% in 2023, then skyrocketed 5266.46% in 2024.
  • A 4-year view of Capital Expenditures shows it stood at $193982.0 in 2022, then plummeted by 297.11% to -$382363.0 in 2023, then soared by 126.83% to $102600.0 in 2024, then plummeted by 101.01% to -$1039.0 in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Capital Expenditures are -$1039.0 (Q4 2025), $8040.0 (Q3 2025), and $160000.0 (Q2 2025).